Success Metrics

Completion Rate

0%(0/1)

Active Trials

4(80%)

Terminated

1(20%)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Recruiting4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

recruiting480%

terminated120%

Recent Activity

4 active trials

Showing 5 of 5

recruitingphase_1

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

NCT06306014

recruitingphase_1

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

NCT06448572

recruitingphase_2

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

NCT06253611

recruitingphase_2

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

NCT06551272

terminatedphase_1

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

NCT05542355

Clinical Trials (5)

Showing 5 of 5 trials

NCT06306014Phase 1

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

Recruiting

NCT06448572Phase 1

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Recruiting

NCT06253611Phase 2

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Recruiting

NCT06551272Phase 2

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

Recruiting

NCT05542355Phase 1

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5